Chapter one · the product
Which medicine is meant?
The word “peptide” covers very different products. Ask for the full name before trying to make sense of an offer.
Review of medicines for particular uses falls to the FDA, the U.S. Food and Drug Administration.
A reviewed product
An approved medicine
Ozempic and Wegovy, both semaglutide products, have FDA approval in the record as of September 26, 2026. note a
A medicine made to order
A compounded drug
Compounding means making a medicine for a patient’s need, usually in a pharmacy.
Compounded drugs lack FDA approval; that status is recorded here as of September 26, 2026. note b
A product sold “for research purposes”
Read the label closely
As of September 26, 2026, FDA records show no U.S. approval for BPC-157.
FDA warns about online products marked “for research purposes” or bearing the warning “not for human consumption”.
Some sellers still give directions for people to use them. note c
Made to order does not mean checked by FDA
Compounded medicines reach sale without FDA first checking their quality, benefits or harms, as of September 26, 2026. note b
Within specific rules, compounding may address a patient’s medical need left unmet by an approved medicine.
The rules depend on the product
U.S. law, as of September 26, 2026, limits regular or large-scale compounding of near-copies of ready-made medicines already on the market.
A change to the medicine may allow it under this rule.
For that patient, the prescriber must find an important difference due to the change.
A patient allergic to a dye, for instance, might need that dye left out when the medicine is made.
A lower bill alone does not meet that test. note d
On September 26, 2026, FDA’s national list of shortages contained neither semaglutide nor tirzepatide.
A local pharmacy’s stock problem is not the same as an entry on the national shortage list. note e
A prescription does not erase a product’s rules
The order a licensed health professional writes for medicine is a prescription.
For retatrutide and cagrilintide, FDA describes a federal-law bar on compounding as of September 26, 2026. note c
Ask for the exact name in writing. Then ask for the reason that product fits the proposed care.
Sources behind this chapter
- FDA: concerns about weight-drug products
FDA urges people to avoid these weight-drug research supplies, citing unknown quality and the possibility of harm.
- FDA: shortage and copying policy updates
These shortage details are dated September 26, 2026; the national listing can change.